Reneo Pharmaceuticals, Inc. (RPHM)
NASDAQ: RPHM · IEX Real-Time Price · USD
1.670
+0.020 (1.21%)
Mar 28, 2024, 1:15 PM EDT - Market open
Reneo Pharmaceuticals Stock Forecast
RPHM's stock price has decreased by -69.19% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts with 12-month price forecasts for RPHM stock have an average target of 11.46, with a low estimate of 1.00 and a high estimate of 30. The average target predicts an increase of 586.23% from the current stock price of 1.67.
Analyst Consensus: Buy
* Price targets were last updated on Dec 15, 2023.
Analyst Ratings
The average analyst rating for RPHM stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Oct '23 | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 3 | 2 | 2 | 2 | 2 |
Buy | 0 | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 3 | 4 | 6 | 6 | 6 | 6 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $30 → $1.5 | Strong Buy → Hold | Downgrades | $30 → $1.5 | -10.18% | Dec 15, 2023 |
Jefferies | Jefferies | Strong Buy → Hold Downgrades $17 → $1.8 | Strong Buy → Hold | Downgrades | $17 → $1.8 | +7.78% | Dec 15, 2023 |
Leerink Partners | Leerink Partners | Buy → Hold Downgrades $1 | Buy → Hold | Downgrades | $1 | -40.12% | Dec 15, 2023 |
William Blair | William Blair | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Nov 15, 2023 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +1,696.41% | Nov 14, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.46
from -2.12
EPS Next Year
-0.85
from -2.46
Revenue Forecast
Revenue | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|---|
High | n/a | n/a | n/a | 205.3M | 354.9M | 529.8M |
Avg | n/a | n/a | n/a | 120.6M | 212.7M | 334.8M |
Low | n/a | n/a | n/a | 40.2M | 77.4M | 149.0M |
Revenue Growth
Revenue Growth | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|---|
High | - | - | - | - | 194.1% | 149.1% |
Avg | - | - | - | - | 76.3% | 57.5% |
Low | - | - | - | - | -35.8% | -30.0% |
EPS Forecast
EPS | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|---|
High | -2.36 | -0.66 | -0.59 | 1.51 | 4.40 | 6.01 |
Avg | -2.46 | -0.85 | -0.70 | 1.47 | 4.27 | 5.83 |
Low | -2.60 | -1.15 | -0.79 | 1.41 | 4.11 | 5.61 |
EPS Growth
EPS Growth | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|---|
High | - | - | - | - | 199.5% | 40.5% |
Avg | - | - | - | - | 191.0% | 36.5% |
Low | - | - | - | - | 179.6% | 31.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.